ALGN vs MMED: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ALGN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALGN and MMED share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALGN and MMED exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Align Technology is a global medical device company best known for Invisalign, the clear-aligner system that has become the dominant alternative to traditional metal braces, and for iTero, its line of intraoral scanners used to capture digital impressions and plan treatment. The business splits into two segments: Clear Aligner, which generated roughly $3.2 billion of Align's approximately $4.0 billion in fiscal 2025 revenue (trailing revenue had reached about $4.14 billion by mid-2026), and Imaging Systems and CAD/CAM services (iTero and exocad software), which added about $0.8 billion. Align sells primarily through orthodontists and general dentists, and its scanners feed cases directly into the Invisalign workflow, creating a self-reinforcing ecosystem.

Full ALGN guide

MiniMed Group is Medtronic's former Diabetes business, headquartered in Northridge, California, with about 8,000 employees and products sold in about 80 countries. It makes automated insulin delivery systems (the MiniMed 780G, and since 2026 the smaller MiniMed Flex), MiniMed Go smart insulin pens, Simplera continuous glucose monitors, and sells the Instinct sensor made by Abbott, all tied together by its own algorithms and app. CEO Que Dallara leads the company.

Full MMED guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ALGN drivers: Clear-aligner market penetration; iTero scanner and digital ecosystem.
• MMED drivers: A full US product cycle; International growth engine.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Growth has decelerated to low single digits as the North American clear-aligner market matures and consumers pull back on discretionary, often out-of-pocket dental spending during economic softness. For MMED, miniMed is unprofitable on a GAAP basis (trailing net loss about $314 million, operating cash flow negative) and has a thin cash balance of about $207 million on its latest balance sheet, so execution on the margin plan matters.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALGN if you believe its drivers more; MMED if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALGN and MMED guides.

ALGN. As of October 16, 2026, Align carried trailing revenue of about $4.14 billion and a market capitalization near $10.6 billion, down from roughly $13 billion in July. At about 12 times forward earnings and 2.6 times sales, the stock no longer trades at the premium multiple it once commanded; the 14 analysts tracked by Yahoo Finance still had a mean target near $194, though several cut targets in October. The third-quarter report on October 28 is the next test of whether volume growth is holding.

MMED. At about 1.5 times sales, MiniMed trades at a steep discount to faster-growing, profitable diabetes-device peers, a gap that reflects its GAAP losses, its recent US share losses and the overhang from Medtronic's exit. On forward earnings the multiple is about 25x. The 15 covering analysts rate it a buy with a mean target near $25, and Rothschild & Co Redburn initiated at buy with a $30 target on October 13, 2026.

Headline figures (approximate, October 2026): ALGN shows revenue (ttm) ~$4.14B, up ~4% YoY in the latest quarter, revenue (q2 2026) ~$1.06B; adjusted EPS $2.64 vs $2.60 expected, margins (ttm) ~71% gross, ~18% operating, ~10% net, net income (ttm) ~$414M GAAP; MMED shows revenue (ttm) ~$3.2 billion; latest quarter up ~17% year over year, gross / operating margin ~57% / ~0.5%, net income (ttm) ~-$314 million; EPS about -$1.53, p/e (forward) ~25x (forward EPS ~$0.69).

ALGN and MMED are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALGN and MMED exposure against your real portfolio. It is not an investment adviser.